Immutep (ASX:IMM) has dosed the first patient in its TACTI-004 phase 3 trial evaluating a potential combination therapy for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The trial is assessing Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with NYSE-listed Merck's Keytruda anti-PD-1 therapy and chemotherapy as first-line treatment for patients with advanced or metastatic non-small cell lung cancer, per the filing.
The study's dual primary endpoints are progression-free survival and overall survival. Results will support a potential marketing approval application.
The global trial will enroll 756 patients at more than 150 clinical sites in over 25 countries, the filing stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。